| 刘小典,王雨来,舒成仁,等.斯鲁利单抗致免疫相关不良反应文献分析[J].安徽医药,2026,30(2):419-424. |
| 斯鲁利单抗致免疫相关不良反应文献分析 |
| Literature analysis of immune-related adverse reactions induced by serplulimab |
| |
| DOI：10.3969/j.issn.1009-6469.2026.02.039 |
| 中文关键词: 药物相关性副作用和不良反应 斯鲁利单抗 程序性死亡蛋白 1(PD-1) 单克隆抗体 文献分析 药学监护 |
| 英文关键词: Drug-related side effects and adverse reactions Serplulimab Programmed death-1(PD-1) Monoclonal antibody Literature analysis Pharmaceutical care |
| 基金项目:湖北省卫生健康委员会联合基金项目( WJ2019H181)；黄石市中心医院科研基金( ZX2023Q10) |
|
| 摘要点击次数: 663 |
| 全文下载次数: 182 |
| 中文摘要: |
| 目的探讨斯鲁利单抗免疫相关不良反应的特点与处理方法，为临床药师在斯鲁利单抗临床治疗过程中发生免疫相关性不良反应的药学监护提供参考。方法全面检索 PubMed、Elsevier Science Direct、Springer-link、Wiley Oline Library、Web of Science、CNKI、万方数据库(截至 2024年 10月)收载的斯鲁利单抗免疫相关不良反应病例报道文献并进行统计与分析。结果共检索到斯鲁利单抗致免疫相关不良反应的个案报道 6例，均为男性，年龄( 59.83±10.91)岁；大多发生在用药后的 6个月内( 5例， 83.33%)，1例发生在用药后 476 d；其中免疫性心肌炎 2例，免疫性肺炎 2例，中毒性表皮坏死崩解症、 1型糖尿病各 1例，均为严重不良反应；经停药及对症治疗后， 4例症状缓解或痊愈， 1例( 1型糖尿病病人)症状缓解后需长期胰岛素治疗， 1例(免疫性心肌炎)因多器官衰竭抢救无效死亡。结论在斯鲁利单抗治疗期间，应对病人进行基线评估和风险评估，提供个体化药物治疗方案，定期进行监测和随访；通过症状体征、实验室指标如心肌损伤标志物、血糖水平以及影像学检查结果等，及时识别和监测免疫相关不良反应；医师与药师协同合作，共同实现对免疫相关不良反应的有效管理，以减少对病人的影响，降低用药风险，保障用药安全。 |
| 英文摘要: |
| Objective To analyze the characteristics and treatment methods of immune-related adverse reactions induced by serplu-limab, and to offer insights for clinical pharmacists in managing these events during serplulimab therapeutic process.Methods Data of PubMed, Elsevier Science Direct, Springer-link, Wiley Online Library, Web of Science, CNKI, and Wanfang database up to October 2024 were retrieved for immune-related adverse reactions induced by serplulimab, and literature were collected for statistical analysis. Results Six cases of immune-related adverse reactions induced by serplulimab were selected, all in male patients with an average ageof (59.83±10.91) years old. Most of them (5 cases, 83.33%) occurred within 6 months, and one case occurred 476 days after medication.Immune-related adverse reactions involved immune myocarditis (2 cases), immune pneumonia (2 cases), toxic epidermal necrolysis (1case), and type 1 diabetes (1 case), and all were serious adverse reactions. After discontinuing the medication and providing symptomat-ic treatment, 4 patients showed improvement or complete recovery, 1 patient showed improvement but required long-term insulin thera-py, and 1 patient died due to multisystem organ failure despite aggressive resuscitation efforts.Conclusions During the treatment withserplulimab, baseline and risk assessments should be conducted for patients, and individualized drug therapy plans should be provided.Regular monitoring and follow-up should be carried out; through symptoms and signs, laboratory indicators such as cardiac injury mark-ers, blood glucose levels, and imaging examination results,immune-related adverse reactions should be timely identified and monitored.Physicians and pharmacists should collaborate to effectively manage immune-related adverse reactions, reduce their impact on patients, lower the risk of medication use, and ensure the safety of medication. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
